Alzheimer's Drug Discovery Foundation

Request For Proposals

Open Request For Proposals (RFPs)

General RFP: The ADDF accepts Letters of Intent (LOIs) for the “General Request for Proposals” research award programs throughout the year. 2013 deadlines for full proposals are January 22, March 5, June 5, September 5 and December 5. LOIs are due at least two weeks prior to the proposal deadlines. See full RFP here.

ApoE RFP: The ADDF and the Robert A. and Renée E. Belfer Family Foundation established The ADDF/Belfer ApoE Therapeutics Innovation Program to accelerate the development of novel therapeutics specifically designed to target apoE pathological mechanisms. This program will allow the ADDF to substantially build on its strategic investment in apoE drug discovery and development and will support both preclinical and clinical stage programs. 2013 deadlines for full proposals are January 22, March 5, June 5, September 5 and December 5. LOIs are due at least two weeks prior to the proposal deadlines. See full RFP here.

PACT RFP: The ADDF has created the Program to Accelerate Clinical Trials (PACT) to increase the number of innovative drugs tested in humans at the crucial proof of concept stage for Alzheimer’s disease. This program will fund biomarker-based, proof-of-concept pilot clinical trials for Alzheimer’s. 2013 deadlines for full proposals are January 22, March 5, June 5, September 5 and December 5. LOIs are due at least two weeks prior to the proposal deadlines. See full RFP here.

NIH RFP: The ADDF will consider financial assistance for relevant NIH grant applications that were scored but not funded in response to certain NIH funding opportunities. See full RFP here.

ADDF-NYAS Challenge Grant: Progress in developing effective Alzheimer’s disease and dementia therapeutics has been hampered by a lack of short-term, sensitive biomarkers that correlate closely to clinical outcomes. The ADDF is partnering with the New York Academy of Sciences (NYAS) to issue a challenge grant for the development and validation of biomarkers that meet this unmet need. Higher priority will be given to applications that involve cross-sector or interdisciplinary collaborations and truly novel ideas. See the full RFP here.

Mitochondria RFP: Mitochondria dysfunction underlies many different diseases.  The brain is particularly vulnerable to changes in energy utilization that occur with age or because of underlying disease pathology.  Novel therapies that can correct defects in mitochondria functioning have the potential to impact many different diseases – from early childhood genetic diseases to late life neurodegenerative diseases such as Alzheimer’s disease.  The Alzheimer’s Drug Discovery Foundation (ADDF) is partnering with the Foundation for Mitochondrial Medicine (FMM) to drive innovative translational research for mitochondrial dysfunction. See the full RFP here.